文献速递冠心病外科瓣膜外科心外重症与机械循环支持

可穿戴心律转复除颤器在多中心大型心脏外科队列中针对一过性心脏性猝死风险的体验

Wearable cardioverter defibrillator multicentre experience in a large cardiac surgery cohort at transient risk of sudden cardiac death.
PubMed 文献 · Eur J Cardiothorac Surg · 2022-01-01

该多中心回顾性研究分析了2010至2020年德国10个心脏外科中心1168例左心室射血分数≤35%或植入式心律转复除颤器取出后使用可穿戴心律转复除颤器的患者,中位佩戴时间23.4小时/天,9.1%患者出现室性心动过速,93.2%发作在最初3个月内,1.5%接受恰当电击,左心室射血分数从28%改善至35%,作者认为可穿戴心律转复除颤器应在此类患者中考虑使用。

要点

  • 心脏外科术后3个月内猝死风险较高,可穿戴心律转复除颤器提供了有效保护。
  • 左心室射血分数从28%改善至35%,多数患者无需植入植入式心律转复除颤器。
  • 尽管有胸骨切开,患者佩戴依从性仍高。

核心结论

  • 心脏外科术后最初3个月内猝死风险显著,可穿戴心律转复除颤器提供了有效保护;由于左心室射血分数显著改善,多数患者使用后无需植入植入式心律转复除颤器;尽管有胸骨切开,依从性仍高;这一多中心经验证实了关于有效性、安全性和依从性的现有数据,因此对于左心室射血分数严重降低的心脏外科患者应考虑使用可穿戴心律转复除颤器。

研究设计与样本

  • 回顾性数据分析,纳入德国10个心脏外科中心2010年至2020年间左心室射血分数≤35%或植入式心律转复除颤器取出后接受可穿戴心律转复除颤器的患者,使用LifeVest Network数据评估。

主要发现

  • 共纳入1168例患者,中位年龄66岁(四分位距57-73),87%为男性。
  • 临床指征包括冠状动脉旁路移植术43%、瓣膜手术16%、冠状动脉旁路移植联合瓣膜手术15%、植入式心律转复除颤器取出24%及其他2%。
  • 可穿戴心律转复除颤器中位佩戴时间为23.4小时/天(四分位距21.7-23.8)。
  • 106例患者(9.1%)出现室性心动过速,93.2%的发作发生在最初3个月内;18例患者(1.5%)接受了26次恰当电击,不恰当电击率低(8例,0.7%)。
  • 左心室射血分数从可穿戴心律转复除颤器处方前中位28%(四分位距22-32%)改善至随访期间35%(四分位距28-42%);排除植入式心律转复除颤器取出患者后,37%的患者接受了植入式心律转复除颤器植入。

临床怎么用

  • 作者认为,对于左心室射血分数严重降低的心脏外科患者应考虑使用可穿戴心律转复除颤器。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The wearable cardioverter defibrillator (WCD) is an established, safe, effective solution, protecting patients at risk of sudden cardiac death. We specifically investigated WCD use in cardiac surgery patients since data for this patient group are rare. METHODS: Retrospective data analysis in 10 German cardiac surgery centres was performed. Cardiac surgery patients with left ventricular ejection fraction (LVEF) ≤35% or after implantable cardioverter defibrillator (ICD) explantation who received WCD between 2010 and 2020 were assessed using LifeVest Network data. RESULTS: A total of 1168 patients with a median age of 66 years [interquartile range (IQR) 57-73] were enrolled; 87% were male. Clinical indications included coronary artery bypass grafting (43%), valve surgery (16%), combined coronary artery bypass graft/valve surgery (15%), ICD explantation (24%) and miscellaneous (2%). The median wear time of WCD was 23.4 h/day (IQR 21.7-23.8). A total of 106 patients (9.1%) exhibited ventricular tachycardia. A total of 93.2% of episodes occurred within the first 3 months. Eighteen patients (1.5%) received 26 adequate shocks. The inadequate shock rate was low (8 patients, 0.7%). LVEF improved from a median of 28% (IQR 22-32%) before WCD prescription to 35% (IQR 28-42%) during follow-up. Excluding ICD explant patients, 37% of patients received an ICD. CONCLUSIONS: The risk of sudden cardiac death is substantial within the first 3 months after cardiac surgery. Patients were protected effectively by WCD. Due to significant LVEF improvement, the majority did not require ICD implantation after WCD use. Compliance was high despite sternotomy. This multicentre experience confirms existing data regarding effectiveness, safety and compliance. Therefore, WCD should be considered in cardiac surgery patients with severely reduced LVEF.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Kuehn C, Ruemke S, Rellecke P, et al. Wearable cardioverter defibrillator multicentre experience in a large cardiac surgery cohort at transient risk of sudden cardiac death. Eur J Cardiothorac Surg. 2022. PMID: 35174386. doi:10.1093/ejcts/ezac086

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。